摩漾生物荣登2021年“时尚100+”时尚医美榜单_Partners_News

摩漾生物荣登2021年“时尚100+”时尚医美榜单

2021-12-30

2021年度“时尚100+”时尚医美榜单近日发布。该榜单围绕科技是时尚、健康是时尚、品牌是时尚三个维度，以先进性、科学性、安全性为框架，从行业引领性、产业价值、社会影响力等多个细分标准来衡量，最终选拔出四家在上海医美领域内的行业标杆企业。其中，恒旭资本投资企业摩漾生物经过“初评筛选+网络票选+专家认定”环节脱颖而出。

关于摩漾生物

上海摩漾生物科技有限公司是一家致力于纳米医用生物材料与可吸收三类植入物产品研发、生产、销售、咨询服务的创新型高新技术企业。摩漾生物将现代时尚理念和医美相融合，依托自身强大的研发制造实力和专业能力，把高科技微纳可吸收材料技术与时尚医美完美结合，为广大医生和就美者提供年轻化全面解决方案。

作为“2021年中国医疗健康最佳投资机构TOP20“和“2019年中国医疗健康产业最具成长性投资机构”的获得者，恒旭资本在医疗行业的布局包括爱博医疗、安智因生物、长风药业、昌郁医药、德美医疗、迪凯尔医疗、高诚生物、励楷科技、魅丽纬叶、摩漾生物、瑞博生物、亚虹医药、微知卓生物、UTC等多家优秀企业。

Address：5th Floor, Building N3, New Bund Square City, No. 2, Lane 131, Qiantan Avenue, Pudong New District, Shanghai

Email：scir@hengxucapital.com

Change of Address Notice

Dear investors and partners,

With your ongoing care and support, Hengxu Capital has achieved significant development and progress since its establishment. In order to better meet the needs of our business operations, our office location will be relocated to 5F, Building N3, New Bund Square City, No. 2, Lane 131, Qiantan Avenue, Pudong New District, Shanghai(Map Link: https://j.map.baidu.com/b5/x7VK).

The new office space is conveniently located with excellent facilities, providing improved conditions for meetings, receptions, and work. This relocation will facilitate better communication and collaboration between Hengxu Capital and our partners, enhancing employee satisfaction and office efficiency, and laying a solid foundation for continued and rapid business development.

The new office has been officially in use since January 29, and our mailing address has been switched to the new location. Considering the approaching Chinese New Year, we will not hold a relocation ceremony at the moment but plan to invite you to visit and guide us at a suitable time in the future.

If you have any questions or concerns, please feel free to contact us. Our phone numbers and email addresses remain unchanged. Once again, we appreciate your support and understanding, and we look forward to creating a brighter future together.

Shanghai SAIC Hengxu Capital Co., Ltd.

Jan. 29, 2024